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antiproteinuric treatment’ [1]. We are pleased to answer
both questions.
First, it is believed that we forgot to mention a few papers.
Before going into the details of the papers mentioned, we
would like to stress the special hallmarks of our patient. She
had infantile nephrotic syndrome, caused by nail-patella
syndrome, as proven by mutation analysis, was treated
exclusively with drugs interfering with the renin–
angiotensin–aldosterone system and went into complete re-
mission with a follow-up of more than 2 years. Indeed,
we did not mention the patient reported by Sreedharan
and Bockenhauer [2]. In fact, this infant, with congenital
nephrotic syndrome of unidentified aetiology, did indeed
go into complete remission with captopril alone, had a re-
lapse when the drug was withheld and responded again,
but the follow-up time was rather short. We did mention
the patient described by Guez et al. [3], but this again
was congenital nephrotic syndrome, this time with the
Finnish type as a most likely diagnosis. But the treat-
ment consisted of indomethacin and enalapril, and the
remission was incomplete at the time of writing. There
are at least two other papers that reported similar pa-
tients treated successfully with indomethacin and capto-
pril [4,5]. The paper by Soliman et al. was, unfortunately,
overlooked for the simple reason that it was not published
yet when we wrote our paper [6]. This baby presented
with infantile nephrotic syndrome; the biopsy showed fo-
cal segmental glomerulosclerosis—which by all means can
hardly be considered an aetiologic category—but no muta-
tion could be identified in the following genes: NPHS1,
NPHS2, WT1 and PLCE1. The patient went into com-
plete remission but with a multidrug regimen consisting
of albumin infusions, furosemide, labetalol, amlodipine,
vitamin E, captopril and enalapril. The follow-up was >1
year, and renal function was estimated to be within the
normal range. Also, we wonder why the title of this pa-
per ends with a question mark, ‘is it renin–angiotensin
blockade?’
Second, the question was raised why we waited for 2 years
before adding losartan to enalapril. From our short Case Re-
port section, it is difficult to explain how well our patient
was doing under enalapril therapy. In this early period of
life, she was never really nephrotic, had no oedema and nor-
mal growth and development. Serum albumin was slightly
below the lower limit of normality and serum cholesterol
slightly above the normal figures for age. Moreover, she
was normotensive with blood pressure figures around the
10th percentile for her age, and therefore it took some time
to reach what we consider the optimal dose of enalapril, i.e.
1 mg/kg. In fact, even if the proteinuria remained almost
constant when calculated in mg/kg with this treatment, it
decreased by the mere fact of growth so that we did not
consider the therapy as futile. Of course, no one could fore-
see how well she would respond to losartan. At the time
this drug was added to enalapril, the first data on the com-
bined therapy in childhood were emerging. When we were
writing our paper, however, we could find only a handful of
paediatric patients in whom this treatment was being used
in the English literature. Even today, there is insufficient
data available about dosages, efficacy, tolerance, side ef-
fects and long-term outcome of paediatric renal patients
treated with the combination of an ACE inhibitor and an
angiotensin–receptor antagonist.
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Low prevalence of chronic kidney disease in Far-East
Asian populations: impact of the ethnicity factor?
Sir,
We read with great interest three epidemiological studies
recently published in Nephrology Dialysis and Transplan-
tation, all studies coming from Far-East Asian countries
(two Chinese and one Japanese) [1–3]. It could be of inter-
est to compare prevalence results of Chinese and Japanese
data. Of course, such a comparison may be difficult and
misleading because the characteristics of the populations
are different: type 2 diabetes in the Japanese study [3]
and the general population in the Chinese studies [1,2].
However, the prevalence of CKD in diabetic patients was
10.2% in the Chinese population [2] versus 15.3% in the
Japanese one [3]. Of course, the differences in ethnicity
and lifestyle may explain such discrepancies. However, we
were also impressed by the differences in the MDRD study
equations used in the Chinese versus Japanese populations.
In Table 1, we show the results of a simulation (man of
age 60 years old) for the MDRD study equation results
applying to different ethnicities. The results are somewhat
intriguing (and constant even if age or sex is modified
in the simulation). Indeed, for the same creatinine value,
the MDRD equation results are logically highest with the
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Table 1. Results of MDRD study equations for a 60 years old man with
different ethnicity factors
MDRD
MDRD Black MDRD MDRD
Caucasian = American = Japanese = Chinese =
175 × 175 × 194 × 175 ×
Creatinine SCr−1.154 × SCr−1.154 × SCr−1.094 × SCr−1.234 ×
(mg/dl) Age−0.203 Age−0.203 × 1.21 Age−0.287 Age−0.179
0.5 170 205 128 198
1 76 92 60 84
1.5 48 58 38 51
2 34 41 28 36
2.5 26 32 22 27
3 21 26 18 22
Black American correction factor. This is classically ex-
plained by the higher muscular mass of Black American
peoples compared to Caucasians [4]. The results are more
astonishing in the comparison of the two Asian equations,
just as they are used in the epidemiological studies. In fact,
for the same creatinine value, the Chinese results are sys-
tematically higher than the Japanese ones. If the Japanese
results are lower than the Caucasian results (which may
perhaps be viewed as logical regarding muscular mass dif-
ferences between these two ethnicities), the Chinese results
are systematically higher (and very close to Caucasians).
The differences in the MDRD study equation results that
are linked to the ethnicity factor would be higher between
Japanese and Chinese patients on one hand than those
between Chinese and Caucasian (or even Black) patients
on the other hand. Differences between Japanese and Chi-
nese MDRD study equations are questionable, strong and
will have a profound impact on the CKD prevalence. We do
not have all data at hand to decide which of the Japanese or
the Chinese equations are the best ones. From our point of
view, the way the Asian equations have been built is very
different (regarding creatinine recalibration, GFR reference
method and statistics used). However, neither the Chinese
nor the Japanese equations are totally free from criticism.
Whatever, the Chinese MDRD results seem systematically
higher than Japanese and Caucasian results that could ex-
plain, at least in part, the lower prevalence of CKD observed
in the Chinese population, notably compared to American
NHANES data. Lastly, it should not be concluded from our
demonstration that the Chinese equation is not accurate.
Indeed, we, and others, have shown that the MDRD study
equation underestimates GFR in a healthy population [5,6]
and thus overestimates the CKD prevalence in epidemio-
logical studies [5]. So, the Chinese MDRD study equation
and the Chinese epidemiological data could be closer to the
‘truth’ than the American and Japanese ones.
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Reply
Sir,
Dr Delanaye and his colleagues compared three epidemio-
logical studies [1–3], two from China [1,2] and one from
Japan [3]. They found that the prevalence of chronic kidney
disease (CKD) was 10.2% in the Chinese diabetic popula-
tion, and 15.3% in the Japanese population. We agree with
the postulation that differences in ethnicity and lifestyle
might be one of the explanations of this discrepancy, but
the vintage of diabetes might add more impact on the ob-
served prevalence. Patients with longer diabetes vintage
were more prone to have CKD.
The simulation of Dr Delanaye and his colleagues was
very impressive. According to the simulation, for three 60-
year-old Caucasian, Chinese and Japanese males, if each of
their plasma creatinine was measured in a local laboratory
and each of the measured values was 1 mg/dL, the esti-
mated glomerular filtration rate (eGFR) would be 84, 76
and 60 mL/min/1.73 m2 calculated from equations for their
own race. We should pay attention to the creatinine value,
1 mg/dL, used in the simulation. If the three plasma sam-
ples were measured simultaneously in one single lab, using
the ‘gold’ creatinine measurement method, they might de-
viate from 1 mg/dL and be different from each other, due to
inter-laboratory variance. Usually, clinicians do not order
‘gold’ creatinine assays, so the systemic difference between
clinically used creatinine measurement methods and ‘gold’
methods was built in each ‘race-specific’ equation.
The modification of diet in renal disease (MDRD) study
[4] used renal clearance of 125I-iothalamate, the Chinese
study [5] used plasma clearance of 99mTc-DTPA and the
Japanese study [6] used renal clearance of inulin as refer-
ence GFR. If there were a ‘gold’ standard of GFR, each of
the three reference GFR methods might deviate from the
‘gold’ standard and be different from each other, due to
